Jeff Sharman, MD, on Improving Response Rates in High-Risk CLL Patients

At the 2017 annual meeting of ASCO, Dr. Jeff Sharman, of The US Oncology Network, presented the findings of his study which suggests that adding ubilituximab to ibrutinib (Imbruvica, Janssen), as treatment for patients with high-risk chronic lymphocytic leukemia, improves response rate without additional clinical toxicity (abstract 7504).